Dark

Check out our Dark Pool Levels

CTIC
CTI BioPharma Corp. (DE) Common Stock
stock NASDAQ

Inactive

Jun 23, 2023

9.09USD0.000%(0.00)11,420,980

Pre-market

0.00USD-100.000%(-9.09)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 6, 2022

04:31PM EST CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Dec 13, 2021

09:08AM EST CTI BioPharma Highlights Presentation Of Data From Pacritinib Program At ASH Meeting Benzinga

09:04AM EST CTI BioPharma Presents Data From Pacritinib Program RTTNews

09:02AM EST CTI BioPharma Presents Data from Pacritinib Program at the 63rd American PR Newswire

Dec 6, 2021

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Dec 2, 2021

04:31PM EST CTI BioPharma to Present at the JMP Securities Hematology & Oncology Summit on PR Newswire

Dec 1, 2021

02:34PM EST Mid-Afternoon Market Update: Dow Rises Over 100 Points; CTI BioPharma Shares Plummet Benzinga

10:07AM EST Mid-Morning Market Update: Markets Open Higher; G-III Apparel Earnings Beat Views Benzinga

08:41AM EST The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case Benzinga

08:36AM EST The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment, Regulatory Setbacks For CTI Biopharma, Favorable Ruling For BioXcel, Viatris In Tecfidera Patent Case Benzinga

06:38AM EST Needham Maintains Buy on CTI BioPharma, Lowers Price Target to $5 Benzinga

Nov 30, 2021

05:36PM EST CTI BioPharma Announces Extension Of FDA Review Period For Pacritinib In Myelofibrosis With Severe Thrombocytopenia; Announces New PDUFA Date Of Feb. 28 Benzinga

05:30PM EST CTI BioPharma Announces Extension of FDA Review Period for Pacritinib in PR Newswire

04:47PM EST The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout Benzinga

Nov 29, 2021

07:03AM EST CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RTTNews

Nov 28, 2021

09:43AM EST The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week Benzinga

Nov 26, 2021

07:08AM EST The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET). RTTNews

Nov 9, 2021

04:06PM EST CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Nov 4, 2021

09:05AM EDT CTI BioPharma Announces Presentations at the 63rd American Society of PR Newswire

Oct 14, 2021

04:06PM EDT CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Oct 4, 2021

10:43AM EDT UPDATE: Needham On CTI BioPharma: Firm Remains Positively Biased For Pacritinib Approval On November 30th For Treatment Of Thrombocytopenic Patients With Advanced Myelofibrosis; Expects Approval By YE21 With 'Projected Sales Of $362M By FY23' Benzinga

10:01AM EDT Needham Reiterates Buy Rating On CTI BioPharma Corp. With $6 Price Target Benzinga

Oct 1, 2021

04:08PM EDT CTI BioPharma Announces Topline Data From Final Analysis Of PRE-VENT Clinical Trial Evaluating Pacritinib As Treatment For Severe COVID-19 Benzinga

04:06PM EDT CTI BioPharma Announces Topline Data from Final Analysis of the PRE-VENT PR Newswire

Sep 28, 2021

04:06PM EDT CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Aug 25, 2021

07:13AM EDT CTI BioPharma, DRI Healthcare Trust Announce Up To $135 RTTNews

07:04AM EDT CTI BioPharma Corp. And DRI Healthcare Trust Announce $135M In Debt And Royalty Transactions Benzinga

07:01AM EDT CTI BioPharma And DRI Healthcare Trust Announce Up To $135 Mln Debt And Royalty Transaction RTTNews

07:01AM EDT CTI BioPharma and DRI Healthcare Trust Announce up to $135 Million Debt and PR Newswire

Aug 24, 2021

07:02AM EDT CTI BioPharma Appoints Diane Parks To Board RTTNews

07:01AM EDT CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors PR Newswire

Aug 9, 2021

10:24AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021 Benzinga

07:40AM EDT BTIG Initiates Coverage On CTI BioPharma with Buy Rating, Announces Price Target of $7 Benzinga

Aug 5, 2021

05:55PM EDT CTI BioPharma Q2 EPS $(0.21), Inline Benzinga

04:09PM EDT CTI BioPharma Q2 Loss/share $0.21 Vs. Loss $0.19 Year Ago RTTNews

04:06PM EDT CTI BioPharma Reports Second Quarter 2021 Financial Results PR Newswire

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 29, 2021

07:01AM EDT CTI BioPharma to Report Second Quarter 2021 Financial Results on August 5, 2021 PR Newswire

Jul 26, 2021

04:31PM EDT CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Jun 9, 2021

07:01AM EDT CTI BioPharma to Present at the JMP Securities Life Sciences Conference on PR Newswire

Jun 1, 2021

04:15PM EDT CTI BioPharma Q1 Loss/share $0.23 Vs. Loss $0.20 Year Ago RTTNews

04:06PM EDT CTI BioPharma Reports First Quarter 2021 Financial Results PR Newswire

09:33AM EDT CTI BioPharma Shares Shoot Higher as FDA Accepts Pacritinib Review Application In Bone Marrow Cancer Benzinga

07:42AM EDT CTI BioPharma Corp. (CTIC) said Tuesday that the U.S. Food and Drug Administration has accepted its New Drug Application or NDA for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia, with the NDA being granted Priority Review. RTTNews

07:06AM EDT CTI BioPharma: FDA Accepts NDA For Pacritinib For Myelofibrosis Patients With Thrombocytopenia RTTNews

07:03AM EDT CTI BioPharma Announces FDA Acceptance Of NDA Granted With Priority Review Of Pacritinib For Treatment Of Patients With Myelofibrosis Benzinga

07:01AM EDT CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of PR Newswire

04:20AM EDT Earnings Scheduled For June 1, 2021 Benzinga

May 26, 2021

04:31PM EDT CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

May 18, 2021

12:16PM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2021 Benzinga

May 12, 2021

08:35PM EDT CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

06:56AM EDT CTI BioPharma Completes Recruitment In Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib Benzinga

May 6, 2021

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2021 Benzinga

07:13AM EDT Stifel Initiates Coverage On CTI BioPharma with Buy Rating, Announces Price Target of $5.5 Benzinga

May 5, 2021

07:01AM EDT CTI BioPharma to Report First Quarter 2021 Financial Results on June 1, 2021 PR Newswire

Apr 21, 2021

11:29PM EDT CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Apr 10, 2021

02:03PM EDT The Past Week's Notable Insider Buys Included Biotechs, Public Offerings, A SPAC And More Benzinga

Apr 7, 2021

07:01AM EDT CTI BioPharma to Present at the 20th Annual Needham Virtual Healthcare PR Newswire

Apr 6, 2021

05:17AM EDT CTI Biopharma Corp 10%+ Owner Mark Lampert Reported Purchase of 2,000,600 Shares @ Avg Price of $10.00/Share in Form 4 Filing on Monday Benzinga

Apr 2, 2021

03:55PM EDT CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Apr 1, 2021

10:14AM EDT Mid-Morning Market Update: Markets Open Higher; CarMax Profit Beats Views Benzinga

07:46AM EDT The Daily Biotech Pulse: Pfizer-BioNTech Preps For BLA Filing, Sonoma Surges, BioXcel Readout, Ortho Clinical Lands Contract Benzinga

Mar 31, 2021

11:54PM EDT CTI BioPharma Announces Pricing Of Public Offering Of Common Stock And Preferred Stock RTTNews

11:51PM EDT CTI BioPharma Corp. Announces Pricing of its Public Offering of Common Stock PR Newswire

04:42PM EDT CTI BioPharma Corp. Announces Proposed Public Offering of Common Stock and PR Newswire

04:42PM EDT CTI BioPharma Reports Offering Of Common Stock, Preferred Shares, No Size Disclosed Benzinga

08:08AM EDT CTI BioPharma Stock Is Trading Higher On Complete Submission For Rolling Pacritinib US Application Benzinga

07:13AM EDT CTI BioPharma Announces Completion of Rolling Submission of New Drug Application for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia Benzinga

07:04AM EDT CTI BioPharma Completes Rolling Submission Of NDA For Pacritinib In Myelofibrosis Patients With Severe Thrombocytopenia RTTNews

07:02AM EDT Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia PR Newswire

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 23, 2021

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

Mar 22, 2021

01:00PM EDT CTI BioPharma's Pacritinib Demonstrates Positive Safety Profile In Graft-Versus-Host-Disease Study Benzinga

10:03AM EDT CTI : Phase 1 Trial Shows Promising Safety Profile Of Pacritinib For Prevention Of Graft-Versus-Host Disease RTTNews

10:02AM EDT UPDATE: CTI Says Phase 2 Investigator-Sponsored Trial Underway To Further Evaluate Clinical Benefit Benzinga

10:02AM EDT UPDATE: CTI Reports 'Phase 1 Trial of Acute GVHD Prophylaxis Following Allogeneic Hematopoietic Cell Transplantation Shows Encouraging Clinical Benefit and Promising Safety Profile' Benzinga

10:02AM EDT CTI BioPharma Highlights Phase 1 Trial Of Pacritinib For Prevention Of Graft-vs-Host Disease Published In Clinical Cancer Research Benzinga

10:01AM EDT Profile of Pacritinib for the Prevention of Graft-Versus-Host Disease Published in Clinical Cancer Research PR Newswire

Mar 17, 2021

04:11PM EDT CTI BioPharma Q4 Loss/share $0.20 Vs. Loss $0.14 Year Ago RTTNews

04:07PM EDT CTI BioPharma Q4 EPS $(0.20) Misses $(0.16) Estimate Benzinga

04:06PM EDT CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results PR Newswire

07:43AM EDT The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes Benzinga

04:01AM EDT Earnings Scheduled For March 17, 2021 Benzinga

Mar 12, 2021

07:01AM EST CTI BioPharma to Report Fourth Quarter and Full Year 2020 Financial Results on PR Newswire

Mar 8, 2021

11:40PM EST CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RTTNews

Feb 25, 2021

07:03AM EST CTI BioPharma to Present at the Cowen 41st Annual Health Care Conference on PR Newswire

Feb 24, 2021

06:30PM EST CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Jan 11, 2021

04:48PM EST CTI BIOPHARMA CORP: OrbiMed Capital GP VI LLC (10%+) Sells 2,000,000 @ Avg Price: $3.50 (Form4) Benzinga

Dec 8, 2020

07:01AM EST CTI BioPharma to Present at The JMP Securities Hematology Summit on Tuesday, PR Newswire

Dec 6, 2020

04:09PM EST CTI BioPharma Announced Presentation of Encouraging Data Supporting Pacritinib's Potential Benefit in Preventing Acute GVHD at ASH 2020 Benzinga

12:30PM EST Benefit in Preventing Acute GVHD at the 62nd American Society of Hematology Meeting PR Newswire

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Nov 30, 2020

07:11AM EST CTI BioPharma Publishes Pacritinib Data From The PAC203 Phase 2 Study In Blood Advances RTTNews

07:04AM EST CTI BioPharma Announces Publication Of Article Highlighting Pacritinib Data From PAC203 Phase 2 Study In Myelofibrosis In Blood Advances Benzinga

07:01AM EST CTI BioPharma Announces Publication of Article Highlighting Pacritinib Data PR Newswire

Nov 24, 2020

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

Nov 10, 2020

04:12PM EST CTI BioPharma Q3 EPS $(0.15), Inline Benzinga

04:08PM EST CTI BioPharma Q3 Loss/Shr $0.15 Vs Loss $0.17 Last Year RTTNews

04:06PM EST CTI BioPharma Reports Third Quarter 2020 Financial Results PR Newswire

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 4, 2020

11:45AM EST CTI BioPharma Announces Oral Presentation Of Phase I Trial Data Of JAK2/mTOR Blockade For GVHD Prevention At The 62nd American Society Of Hematology Meeting On Dec. 6 Benzinga

11:42AM EST CTI BioPharma Announces Oral Presentation at the 62nd American Society of PR Newswire

Nov 2, 2020

04:06PM EST CTI BioPharma to Report Third Quarter 2020 Financial Results on November 10, PR Newswire

Oct 23, 2020

10:48AM EDT Benzinga's Top Upgrades, Downgrades For October 23, 2020 Benzinga

06:09AM EDT Brookline Capital Initiates Coverage On CTI BioPharma with Buy Rating, Announces Price Target of $7 Benzinga

Oct 13, 2020

07:01AM EDT CTI BioPharma Initiates Rolling Submission Of NDA For Pacritinib In Myelofibrosis Patients With Severe Thrombocytopenia RTTNews

07:01AM EDT CTI BioPharma Initiates Rolling Submission Of New Drug Application (NDA) For Pacritinib In Myelofibrosis Patients With Severe Thrombocytopenia Benzinga

07:01AM EDT CTI BioPharma Initiates Rolling Submission of New Drug Application (NDA) for PR Newswire

Sep 30, 2020

03:55PM EDT Mid-Afternoon Market Update: Dow Jumps 350 Points; Iterum Therapeutics Shares Spike Higher Benzinga

12:45PM EDT Mid-Day Market Update: Crude Oil Rises Over 1%; Aptorum Group Shares Plummet Benzinga

10:59AM EDT Needham Maintains Buy on CTI BioPharma, Raises Price Target to $6 Benzinga

09:58AM EDT Shares of CTI BioPharma Corp. (CTIC) are skyrocketing more than 100 percent or $1.05 in Wednesday's morning trade at $2.10, after touching a new 52-week high of $2.58. RTTNews

Sep 29, 2020

04:09PM EDT UPDATE: CTI Says Will Proceed With Rolling New Drug Application Submission, Sees Rolling NDA Commencing In Q4'20, Sees Completion Of NDA Submission In Q1'21 Benzinga

04:08PM EDT CTI BioPharma Shares To Resume Trade At 4:35 p.m. EDT Benzinga

04:07PM EDT CTI BioPharma Reports Submission Of New Drug Application For Accelerated Approval Of Pacritinib For Treatment Of Myelofibrosis Patients With Severe Thrombocytopenia Benzinga

04:05PM EDT Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia PR Newswire

04:03PM EDT CTI BioPharma Shares Halted News Pending Benzinga

Aug 6, 2020

04:28PM EDT CTI BioPharma Q2 EPS $(0.19), Same YoY Benzinga

04:25PM EDT CTI BioPharma Q2 Loss/Shr $0.19, Same As Last Year RTTNews

04:06PM EDT CTI BioPharma Reports Second Quarter 2020 Financial Results PR Newswire

Share